Doctolib

When Doctolib launched its first product in November 2013 with 50 doctors, French healthcare still ran on phone calls, paper diaries, and voicemail. Stanislas Niox-Chateau, a former junior tennis champion turned HEC Paris entrepreneur, had already helped build TheFork and a beauty-booking site, so he knew the playbook: take a fragmented, offline market and give it a booking engine people actually want to use.

A decade later the bet has compounded. Doctolib now says it serves more than 420,000 health professionals and 90M patients across France, Germany, Italy, and the Netherlands, employs roughly 2,900 people, and in 2022 hit a $6.4B valuation that made it France's most valuable startup. The next act is AI and an overseas push into the UK, with the eventual prize a public listing.

Doctolib is a full software suite for healthcare, not just the booking widget most people know it by. Patients use it to find a practitioner, book 24/7, get reminders, and do video consultations; doctors and clinics use it to run their calendar, keep electronic health records, message securely, prescribe, and handle billing and insurance.

That spread is the point. The consumer app is the front door that brings in patients, and the professional software is where the money and the lock-in live. Doctolib describes itself as a purpose-driven company, a French societe a mission, with social objectives written into its charter and audited each year.

The core problem Doctolib attacks is administrative drag. Practices lose hours to booking calls, no-shows, chasing paperwork, and manual records, and patients lose time and access when the only way to reach a doctor is a phone line that rings out.

Online booking with reminders cuts no-shows and moves demand off business hours; the company says half of the 15M appointments booked monthly in France happen outside office hours. The newer AI push aims squarely at the documentation burden, with a consultation assistant Doctolib says has already supported 5M consultations and a stated goal of saving a GP around 4.5 hours a week.

Doctolib is a two-sided platform, but the customer that pays is the healthcare professional: solo GPs, specialists, physios, dentists, opticians, clinics, and public hospitals such as AP-HP in Paris. The patient side is free, and the sheer size of that patient base is what pulls professionals onto the platform.

The deep localization is deliberate. Each market gets products tuned to its regulations, languages, and specialties, which is why Doctolib fields large field-sales teams city by city across France and Germany rather than selling purely online.

The suite has grown well past scheduling into records, telemedicine, care coordination, and now a stack of AI assistants. The through-line is keeping a practice's entire day inside one system so the pieces talk to each other.

The AI assistants are the newest and most strategic layer, split across the clinician's documentation and phone lines and the patient's own health companion.

Doctolib makes money the classic SaaS way: patients book for free, and healthcare professionals pay a recurring subscription for the booking, records, telemedicine, and admin tools. The consumer app is effectively customer acquisition for the paid professional software.

The company does not publish pricing, and reviewers note cost is a real consideration for smaller practices weighing the subscription. Doctolib has spent recent years pushing toward profitability, narrowing an adjusted EBITDA loss of around 87M euros in 2023 toward a targeted breakeven in 2025 ahead of a possible IPO.

In France, Doctolib is close to the default, which is both its moat and its regulatory exposure. Its real edge is the network effect: a huge patient base makes it the obvious place for a doctor to be listed, and every new doctor makes the app more useful to patients.

Outside France the fight is live. Germany, Italy, and the Netherlands are less locked up, and the 2026 acquisition of Medicus Health, the first new core clinical system NHS England approved in 25 years, is Doctolib's opening move on the UK. The company's bet is that a single localized, AI-native platform beats a patchwork of point tools.

The scale claims are the pitch: 420,000-plus health professionals, 90M patients, and 15M appointments booked monthly in France, roughly half outside office hours. On the AI side, the company says its consultation assistant has supported 5M consultations.

These are company-reported figures, but the outside markers line up. Revenue of around 257M euros, a $6.4B valuation, B Corp certification, and ISO 27001 and HDS (French health-data hosting) certifications all point to a business operating at genuine European scale.

The recurring praise from patients is friction removal: booking online in a few taps, reminders that cut no-shows, and a lifeline for anyone who struggles to call a practice, especially non-native speakers in Germany. Providers like running their schedule in one place without the double-booking chaos.

The recurring gripes are just as consistent. Patients complain about stale or inaccurate doctor info, getting deep into a booking only to hit an insurance or new-patient wall, and gaps in language and location detail. For providers, the cost of the subscription is the sticking point. The sentiment nets out positive on convenience, with accuracy and price as the sore spots.

Doctolib has raised on the order of $866M from a heavyweight roster including General Atlantic, Eurazeo, Accel, and France's own Bpifrance. The headline round came in March 2022: 500M euros (about $549M) in equity and debt led by Eurazeo, at a $6.4B valuation that made it the most valuable startup in France.

Since then the story has shifted from raising to proving. Reporting in late 2025 pointed to a possible secondary investment at a roughly flat valuation, and management has openly framed profitability as the prerequisite for an IPO expected around late 2026 or 2027.

Doctolib enters its second decade with the French market largely won and three things left to prove: that it can turn a real profit, that its AI assistants deliver the hours-saved they promise rather than just demo well, and that the platform travels beyond France as cleanly as it scaled at home.

The UK expansion and the profitability push are the same bet from two angles, both pointed at a public listing. The risk is the familiar one for a category leader: being the default invites the regulatory and pricing scrutiny that comes with owning the front door to a country's healthcare.

Doctolib leans hard on its purpose, framing the work as building the healthcare people actually want and backing it up with B Corp certification and societe a mission status audited each year. For engineers, the draw is scale: a roughly 900-person tech and product org building for millions of patients on a single cloud-native platform.

The benefits are generous and unmistakably European. Fully paid health insurance for you and your kids, 25 vacation days plus up to 14 RTT days, an extra month of parental leave via the Parent Care Program, free mental-health coaching through Moka.care, Swile lunch vouchers, and hybrid work with up to 10 days a year from abroad. Hybrid means real office time, typically two to three days a week, mostly out of the Paris HQ in Levallois-Perret.

Disclosed pay in the postings is in euros and spread across France and Germany. Sales and field-commercial roles cluster at the lower-to-mid range typical of on-target commission jobs, while product and senior engineering roles sit meaningfully higher.

Base is only part of the package. Doctolib enrolls employees in a long-term value-sharing plan it calls DoctoGrowth, and sales roles carry commission on top of base, so the disclosed bands understate total comp for those functions.

Handling patient records across Europe puts compliance at the center of the product, not the footnotes. Doctolib operates as a French SAS headquartered at 54 quai Charles Pasqua in Levallois-Perret, and its legal terms and privacy policies live on a dedicated doctolib.legal domain.

The company states ISO 27001 and HDS certification, HDS being France's mandatory standard for hosting health data, and its engineering job posts describe pseudonymization pipelines that convert personal identifiers to anonymized data and GDPR-aligned handling built into the data platform.

The big recent story is geographic. In May 2026 Doctolib acquired UK GP-software supplier Medicus Health, pledging more than 100M pounds of UK investment, 150 hires, and a London R&D center focused on primary care.

The strategic subtext, widely reported, is that the UK was the last major market Doctolib needed to justify a multi-billion-dollar IPO, timed for once profitability lands.